Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — OncoCyte — Investor Presentation (January 2018)
29 slides from Insight Molecular Diagnostics's investor presentation, Jan 8, 2018
Slide 1: Advancing Cancer Diagnosis
& Advancing Cancer Diagnosis Improving patient outcomes while lowering health care costs jam Annett Chief Executive Officer ich Levine Chief Financial Officer cu te” NYSE AMERICAN:
Slide 2: Forward Looking Statements
Forward Looking Statements ‘Statements pertaining to future financial andlor operating results, future research, diagnostic tests, and technology under development, clinical development of diagnostic tests, and potential ‘opportunities for OncoCyte Corporation and the diagnostic tests itis developin
Slide 3: Overview
Overview OncoCyte develops and commercializes novel blood tests for the early detection of cancer. Market Data Ticker (NYSE American) Ocx Price (12/29/2017) $4.65 52-Week Range $3.60-7.85 Market Cap ~$145M Average Daily Trading (3mos) _~25,000 Common Shares Outstanding 313M Covering Research Analyst
Slide 4: Investment Highlights
Investment Highlights + Focused on largest markets with unmet needs for early, accurate cancer diagnosis © Lung confirmatory market projected $4+ billion + Compelling value proposition for physicians, patients, and payers © Potential for fewer risky procedures and significant cost savings + Launch o
Slide 5: Experienced Life Science Leadership Team
Experienced Life Science Leadership Team Position Experience Wiliam Annett President CEO CEO BioFx Labs: CEO Corea Life Sciences: Managing Oector ‘Accenture Life Science: Led Commercial Stategy Project Finance Genentech: Harvard MBA Mitch Levine cro Founder Kirby Cove Capital Advisors Founder Enable
Slide 6: Early diagnosis — the largest market segment with least competition
Early diagnosis — the largest market segment > with least competition Pre-Diagnosis Post-Diagnosis DATION Low barriers to i OncoCyte-
Slide 7: Strategically focused on areas of greatest unmet need and most attractive margins
Strategically focused on areas of greatest unmet need and most attractive margins Product Contribution Opportunity ($Bs) 90% Lung Confirmatory Fy $39 bola 4 Colorectal ge $3.2 Ovarian soe 33 @ S502 ae Breast ax 3 Contirmatory ig $5.4 ules oposont prt 10% + cheno © oss Thyroid gy Prostate terns algae
Slide 8: Advancing the Standard of Care in cancer diagnosis
Advancing the Standard of Care in cancer P diagnosis IP Protected gene expression classifier with binary call Cal Be Liguld Biopsy Blomarkers Classifier Suspicious" Tost Results IP Protection ‘Biomarkers: Method of Use Patent flad in muliplejuredictions (Classifier: Proprietary, protected under trad
Slide 9: Lung Opportunity
Lung Opportunity Cute
Slide 10: Lung is one of largest US market opportunities
Lung is one of largest US market opportunities => $4.7B Initial use Expanded use 400,000-600,000 Patients with 1.4 Million Patients with large nodules medium to large nodules * « SSSA Cesc yb
Slide 11: Large market opportunity for lung tests
Large market opportunity for lung tests Lung Imaging Overall Lung Nodule Market (10-15 Million Patients) 4 g Lung-RADS 3 & 4 (25mm) 2 (LA Milion Patients) g He g Downstream procedures - performed on 5 tung-RADS 4 (28mm) FA indeterminate 2 diagnoses § * OncoCyte-
Slide 12: Lung opportunity driven by poor outcomes
Lung opportunity driven by poor outcomes Lung cancer is typically diagnosed at later stages, with 57% of diagnoses made in stage IV, limiting survival rates ‘Ato wei ra seer te Prostate Breast Bladder Lung * OncoCyte-
Slide 13: Post-LDCT biopsies are risky and expensive
Post-LDCT biopsies are risky and expensive + Lung biopsies — via needle, bronchoscopy or surgery — are much riskier than other cancer biopsies 051% Moraity 00-1.300 20% Major '5.000-28.000 complicatons (oatusng colapeed ung) For an average patient, + Mean cost of $14,634 per biopsy err aon ea + Freq
Slide 14: Reducing unnecessary biopsies
Reducing unnecessary biopsies 7-10M Americans, Contermatary, oO Highsk, 20 Packeyear history USPSTF Guidelines recommend — 8 Malignant sereening covered by Meoae Q = “6 surpous Q =< Q@ H @ 5 J g . 4 A 8 ‘5M Americans Incidentaly screened patents * OncoCyte-
Slide 15: DetermaVu could significantly improve Standard of Care
DetermaVu could significantly improve Standard of Care ‘AMultigene Classifier for the Diagnosis of Benign vs Malignant Pulmonary Nodules + 95% Sensitivity + 73% Specificity pes ard Improves health outcomes af ath Reduces number of biopsies 2B oso Pk darker Fewer complications aan Fewer deaths hea oo
Slide 16: Clinical validation study update
Clinical validation study update + Extensive analysis of issues ¥ Root cause analysis performed ~ Continue to believe source is vendor consumables manufacturing ¥ Confirmed OCX data to date is reliable + Next steps © Vendor lot manufacturing run (January) © Quality control testing © If successful —
Slide 17: Final studies provide path to commercialization
Final studies provide path to commercialization Pre-Launch RAD verific + Clinical validation — confirms that the diagnostic test can be run ina commercial lab and meets the appropriate regulatory and clinical standards + Clinical utility - assess the healthcare economics associated with a diagnostic
Slide 18: Potential for up to $4.7B in annual US cost offsets
Potential for up to $4.7B in annual US cost offsets High clinical utility — the potential for fewer risky procedures and significant cost offsets Current standard of care OncoCyte’s test as part of standard of care * OncoCyte-
Slide 19: Physicians in target specialties express highest level of interest
Physicians in target specialties express > highest level of interest OncoCyte’s test is a compelling value proposition for physi Interest in using lung test Oncologists Radiologists Interventional Pulmonologists, radiologists 33 Reasons provided for high ratings: Useful for smaller nodules with high
Slide 20: Commercialization strategy addresses all key stakeholders
Commercialization strategy addresses all key stakeholders Deteminate agnosis ‘Eater cetecton Improves heath High senstuty, Improved outcomes ‘ucomes: ene Resuoe amie ver Fewer umecessary Benefits Recuce unecessary ‘sasteminate fing Bopsies Reduce overal cos a OncoCyte-
Slide 21: Sales strategy focused on targeted physician specialties
Sales strategy focused on targeted P physician specialties ‘Small specialty sales force ramps-up as coverage is gained Specialty Sales Force * OncoCyte-
Slide 22: Reimbursement strategy has three key components
Reimbursement strategy has three key D components & = Oncocyte"
Slide 23: Successful trials expected to result in reimbursement
Successful trials expected to result in reimbursement + Strong clinical validation and utility studies are key to coverage + OncoCyte's strategy is to provide the highest level of evidence to increase probability of both CMS and private payor coverage + Previewed study designs with payers — 10 Publi
Slide 24: Focused reimbursement strategy supports value-based pricing
Focused reimbursement strategy supports ES] > value-based pri PAMA Maintains value-based pricing MAAA Creates value-based price Optimi contracting strategy = OncoCyte test is MAAA* ene Bevel contacting = Medicare price based on é strategy maintains weighted commercial median Uniaile CPT code: value-
Slide 25: Key milestones
Key milestones Completed Completed 2018 2018 Post-launch 2018-19 2019 Analytical Validation study CLIA Certification DetermaVu™ Lung clinical validation study Planned commercial launch of DetermaVu Ongoing clinical utility studies Submit application/dossier for Medicare coverage Medicare coverage de
Slide 26: Market cap is correlated to market opportunity and reimbursement coverage
Market cap is correlated to market opportunity and reimbursement coverage z § 4 2 & @ OncoCyte cd voter s141M “ec eo © Low ‘Medium High Market Opportunity * 3s Ekinrcmiegnaaye nn MORSE Mee nee scorer siamese OncocCyte-
Slide 27: Financial highlights and capitalization
Financial highlights and capitalization ($/000s) September 30, 2017 Cash and equivalents $11,024M Marketable securities SIM Total Current Assets 12,484 Total Assets 14,249 Total Current Liabilities 4,637 Long Term Debt 6,201 Stockholders’ Equity 8,048 Total Liabilities and Stockholders Equity $14,24
Slide 28: Investment Highlights
Investment Highlights + Focused on largest markets with unmet needs for early, accurate cancer diagnosis © Lung confirmatory market projected $4+ billion + Compelling value proposition for physicians, patients, and payers © Potential for fewer risky procedures and significant cost savings + Launch o
Slide 29: jam Annett
jam Annett Chief Executive Officer ich Levine Chief Financial Officer NYSE AMERICAN: Liquid Biopsies Advancing cancer diagnosis